Please find the attached Scrutinizer Report for EOGM
Awaiting price reaction for this filing.
Raymed Labs Limited (BSE scrip code 531207) held an Extra-Ordinary General Meeting on 21st April 2025 and all 11 resolutions put to vote were passed with overwhelming majority, with over 99% of votes in favour in every case. Key resolutions include a change of the company's name (with amendment to the MoA and AoA), alteration of the main object clause in the MoA, and appointment of Mr. Prashant Bajaj as Managing Director. Six additional directors were regularised as Non-Executive or Independent Directors. Shareholders also approved loans/investments under Section 185 of the Companies Act and material related party transactions. A small group of 6 members holding just 410 shares voted against each resolution, while no votes were declared invalid.
The biggest takeaway for shareholders is the approved change of company name and the overhaul of the board with several new director appointments and regularisations. The passage of related-party transaction and Section 185 loan resolutions gives management wider flexibility for funding and dealings with related entities, which minority shareholders should monitor closely.